Garcia-Tsao G et al. Double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension (PH). (Abstract LB-01),Garcia-Tsao G, et al. Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension. Hepatology. 2019;69:717-28.
Marie Skłodowska-Curie Action-beurs voor Bernadette van den Hoogen
jul 2019 | Virale infecties